Jenny Z. Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jenny Z. Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Emanual Maverakis
Department of Dermatology, University of California Davis School of Medicine, Sacramento, CA
3 shared publications - Stephanie T. Le
Department of Dermatology, University of California , Davis, Sacramento, CA , USA
2 shared publications A. Sood
Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA
1 shared publicationA. Toussi
Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA
1 shared publication- Alexander Merleev
Department of Dermatology, University of California Davis Medical Center, Sacramento, CA, USA
1 shared publication - Alina I. Marusina
Department of Dermatology, University of California, Davis, Sacramento, California, USA
1 shared publication
Latest Publications
- 11 July 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (4) , 496-498
A qualitative exploration of patient experiences in pyoderma gangrenosum
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that is associated with a decreased quality-of-life (QoL). There are no PG-specific patient-reported outcome measures. In this exploratory study, we use patient interviews to define QoL domains in PG that will inform future outcomes measures.
- 11 July 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (4) , 496-498
A qualitative exploration of patient experiences in pyoderma gangrenosum
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that is associated with a decreased quality-of-life (QoL). There are no PG-specific patient-reported outcome measures. In this exploratory study, we use patient interviews to define QoL domains in PG that will inform future outcomes measures.
- Open Access
- 2 April 2020
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 24 (3) , 278-284
Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review
Tumor necrosis factor (TNF) inhibitors have been used as an excellent therapeutic option in a variety of chronic inflammatory conditions. However, a recognized significant adverse effect of TNF inhibitor therapy is the increased risk of infections. The influence of TNF inhibitors on the course of coexisting or newly developed viral infections has not been extensively investigated. Therefore, we reviewed the recent publications to highlight the incidence, clinical features, management, and prevention of herpes zoster in patients who are receiving TNF inhibitors.
- 2 April 2020
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 24 (3) , 278-284
Open AccessIncidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review
Tumor necrosis factor (TNF) inhibitors have been used as an excellent therapeutic option in a variety of chronic inflammatory conditions. However, a recognized significant adverse effect of TNF inhibitor therapy is the increased risk of infections. The influence of TNF inhibitors on the course of coexisting or newly developed viral infections has not been extensively investigated. Therefore, we reviewed the recent publications to highlight the incidence, clinical features, management, and prevention of herpes zoster in patients who are receiving TNF inhibitors.
- 30 October 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (2) , E108-E110
Peristomal ulcers misdiagnosed as pyoderma gangrenosum: a common error
- 30 October 2019
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (2) , E108-E110
Peristomal ulcers misdiagnosed as pyoderma gangrenosum: a common error
- Open Access
- 8 March 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (3) , 633-634
Development and initial validation of the trace‐to‐tape method: an objective outcome measure for linear postoperative scars
- 8 March 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (3) , 633-634
Open AccessDevelopment and initial validation of the trace‐to‐tape method: an objective outcome measure for linear postoperative scars
- Open Access
- 1 January 2019
- Published by XMLink in The World Journal of Men's Health
- Vol. 37 (3) , 313-321
No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma
Wang JZ, et al. World J Mens Health. 2018 Jan;36:e36. https://doi.org/10.5534/wjmh.180050
- 1 January 2019
- Published by XMLink in The World Journal of Men's Health
- Vol. 37 (3) , 313-321
Open AccessNo Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma
Wang JZ, et al. World J Mens Health. 2018 Jan;36:e36. https://doi.org/10.5534/wjmh.180050
- 11 December 2017
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 19 (3) , 333-344
Granuloma Annulare: A Focused Review of Therapeutic Options
Granuloma annulare (GA) is a benign inflammatory disease associated with many conditions such as malignancy, trauma, thyroid disease, diabetes mellitus, and HIV infection. Common clinical subtypes include localized GA, generalized GA, subcutaneous GA, perforating GA, and patch GA. There exists an abundance of literature on GA, yet we know relatively little about its exact etiology and even less about its treatment. The paucity of conclusive data on effective treatment options is largely because the majority of published studies are limited to small case reports, case series, and retrospective studies. As such, there does not yet exist a gold standard of care to guide clinical management. Depending on the clinical subtype, the clinical prognosis for GA can vary. The localized variant generally self-resolves within 2 years without treatment, whereas the generalized form is more chronic and less responsive to treatment. This focused up-to-date review serves to summarize the latest therapeutic options available for GA.
- 11 December 2017
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 19 (3) , 333-344
Granuloma Annulare: A Focused Review of Therapeutic Options
Granuloma annulare (GA) is a benign inflammatory disease associated with many conditions such as malignancy, trauma, thyroid disease, diabetes mellitus, and HIV infection. Common clinical subtypes include localized GA, generalized GA, subcutaneous GA, perforating GA, and patch GA. There exists an abundance of literature on GA, yet we know relatively little about its exact etiology and even less about its treatment. The paucity of conclusive data on effective treatment options is largely because the majority of published studies are limited to small case reports, case series, and retrospective studies. As such, there does not yet exist a gold standard of care to guide clinical management. Depending on the clinical subtype, the clinical prognosis for GA can vary. The localized variant generally self-resolves within 2 years without treatment, whereas the generalized form is more chronic and less responsive to treatment. This focused up-to-date review serves to summarize the latest therapeutic options available for GA.